Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients

Informacje na temat projektu

XTremedy Medical

Identyfikator umowy o grant: 101069625

DOI

10.3030/101069625

Projekt został zamknięty

Data podpisania przez KE 20 Czerwca 2022

Data rozpoczęcia 1 Lipca 2022

Data zakończenia 31 Grudnia 2022

Finansowanie w ramach

• European innovation ecosystems

Koszt całkowity

Brak danych

Wkład UE

€ 75 000,00

Koordynowany przez

XTREMEDY MEDICAL LIMITED
Ireland

Periodic Reporting for period 1 - XTremedy Medical (Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients)

Okres sprawozdawczy: 2022-07-01 do 2022-12-31

Podsumowanie kontekstu i ogólnych celów projektu

XTremedy Medical are a surgical device company developing treatments for infected wounds, in particular Diabetic Foot Ulcers (DFUs). Infection has now been recognised as a leading cause of wound chronicity - wounds that do not respond to initial treatments.i Infections that spread to deep muscle and bone tissues, are the leading cause of amputations in diabetics. Biofilms, a type of infection often found in wounds, are complex to treat with up to 1000-fold tolerance to antibiotics.ii High concentrations of antibiotics required to treat these infections impairs kidney function and leads to high rates of kidney failure.
XTremedy Medical overcomes limitations with current solutions by treating both surface and subsurface tissues without disrupting tissue structures. XTremedy’s first device – BioBlate, is a non-thermal ablation device using pulsed electric field ablation (PFA) to treat biofilms. PFA is known for its anti-microbial and non-destructive properties.
Incorporating BioBlate technology enables the surgeon to remove all biofilm within the wound without removing excess healthy tissue which impairs healing. Delivering wound margins free of biofilm leads to fewer surgeries and shortened hospital stays

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

Commercialisation (regulatory and market access) strategy mapped for BioBlate technology

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

Xtremedy have demonstrated that thier PFA device is up to 1000x more effective at removing biofilm/bioburden than the standard of care (saline flush). Using the BioBlate device, the team achieved 6 log reductions in ex-vivo staph epidermis biofilms and 4 log reductions in staph aureus. This is compared to <1 log reduction with the standard of care, a saline flush. These results have been validated in a third party lab.